Leukemia in Europe & Central Asia
Death rates for Leukemia across 58 countries in Europe & Central Asia.
| # | Country | Rate |
|---|
Leukemia encompasses a group of blood cancers originating in the bone marrow and resulting in the overproduction of abnormal white blood cells. Collectively, leukemias cause approximately 310,000 deaths per year worldwide. The four main types — acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML) — have distinct age distributions, prognoses, and treatment paradigms. ALL is the most common childhood cancer, with cure rates exceeding 90% in high-income countries but remaining below 30% in many low-income settings due to treatment abandonment, infection, and limited supportive care. AML is predominantly a disease of older adults and carries one of the poorest prognoses among cancers. CML was transformed by the introduction of imatinib (Gleevec) in 2001, converting a fatal disease into a manageable chronic condition. Risk factors include ionizing radiation exposure, benzene, prior chemotherapy, and certain genetic syndromes (Down syndrome, Fanconi anemia). The survival gap between high-income and low-income countries for childhood leukemia is one of the largest inequities in global oncology. Europe and Central Asia benefit from relatively strong health systems and high physician density, but face ageing populations, rising non-communicable disease burdens, and persistent East-West health outcome gradients. In Europe & Central Asia, leukemia mortality is near global averages, though the region exhibits a marked gradient between Western European countries with low rates and Central Asian nations facing higher burdens.
Unlike many solid tumors, leukemia has few modifiable risk factors — avoiding unnecessary ionizing radiation and occupational benzene exposure are the primary preventive strategies. For childhood ALL, the critical intervention is ensuring access to multi-agent chemotherapy protocols and adequate supportive care (blood banking, infection management, nutritional support). Twinning partnerships between high-income and low-income cancer centers have demonstrated significant improvements in childhood ALL survival. For CML, universal access to tyrosine kinase inhibitors (now available as generics) can dramatically reduce mortality. AML treatment advances include targeted therapies for specific mutations (FLT3, IDH1/2) and improved understanding of minimal residual disease monitoring. Bone marrow transplant registries and cord blood banking expand curative options for eligible patients.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for leukemia in Europe & Central Asia, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
Cancer mortality data combine information from population-based cancer registries, vital registration systems, and statistical modeling where direct data are sparse. Incidence-to-mortality ratios and survival estimates help distinguish regions where high death rates stem from high incidence versus those where limited access to early detection and treatment drives poor outcomes. For leukemia across Europe & Central Asia, comparing mortality rates alongside screening coverage and treatment availability provides crucial context for understanding regional disparities.